Stock Events

Stock Events

Dynavax Technologies 

$15.49
111
+$0.01+0.03% Today

Statistics

Day High
15.5
Day Low
15.48
52W High
15.73
52W Low
9.2
Volume
810,286
Avg. Volume
3,049,193
Mkt Cap
1.82B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19FebExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.77
-0.44
-0.12
0.21
Expected EPS
0.038833
Actual EPS
N/A

Financials

9.85%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
554.49MRevenue
54.62MNet Income

Analyst Ratings

$32.00Average Price Target
The highest estimate is 32.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DVAX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.36B
Novavax is a direct competitor in the vaccine development space, particularly for COVID-19, where both companies have significant investments.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a leader in mRNA vaccine technology, competing with Dynavax's adjuvant technology in developing vaccines for infectious diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, with its broad portfolio including COVID-19 vaccines, competes in the same market as Dynavax, especially in vaccine development and distribution.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the vaccine market, including COVID-19, where Dynavax also operates.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline competes with Dynavax in the development of vaccines, including their adjuvant systems used to enhance vaccine efficacy.
Sanofi
SNY
Mkt Cap124.45B
Sanofi competes in the vaccine market, including flu vaccines, where Dynavax also has products, making them direct competitors.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes with Dynavax in the COVID-19 vaccine space, among other areas, making them significant competitors in pandemic response efforts.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech, in partnership with Pfizer, competes directly with Dynavax in the COVID-19 vaccine market, leveraging mRNA technology.
CureVac N.V.
CVAC
Mkt Cap1.2B
CureVac competes in the mRNA vaccine space, similar to Dynavax's involvement in vaccine technology, particularly for infectious diseases.

About

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Show more...
CEO
Mr. Ryan Spencer
Employees
405
Country
US
ISIN
US2681582019

Listings

F
DE
DYF1.F
LSE
GB
0IDA.LSE
XNAS
US
DVAX
BOATS
BOATS
DVAX.BOATS

0 Comments

Share your thoughts

FAQ

What is Dynavax Technologies stock price today?▼
The current price of DVAX is $15.49 USD — it has increased by +0.03% in the past 24 hours. Watch Dynavax Technologies stock price performance more closely on the chart.
What is Dynavax Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Dynavax Technologies stocks are traded under the ticker DVAX.
Is Dynavax Technologies stock price growing?▼
DVAX stock has fallen by -0.19% compared to the previous week, the month change is a +0.72% rise, over the last year Dynavax Technologies has showed a +18.7% increase.
What is Dynavax Technologies market cap?▼
Today Dynavax Technologies has the market capitalization of 1.82B
When is the next Dynavax Technologies earnings date?▼
Dynavax Technologies is going to release the next earnings report on February 19, 2026.
What were Dynavax Technologies earnings last quarter?▼
DVAX earnings for the last quarter are 0.21 USD per share, whereas the estimation was 0.13 USD resulting in a +66.57% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dynavax Technologies revenue for the last year?▼
Dynavax Technologies revenue for the last year amounts to 554.49M USD.
What is Dynavax Technologies net income for the last year?▼
DVAX net income for the last year is 54.62M USD.
How many employees does Dynavax Technologies have?▼
As of February 02, 2026, the company has 405 employees.
In which sector is Dynavax Technologies located?▼
Dynavax Technologies operates in the Health Care sector.
When did Dynavax Technologies complete a stock split?▼
The last stock split for Dynavax Technologies was on November 10, 2021 with a ratio of 1:10.
Where is Dynavax Technologies headquartered?▼
Dynavax Technologies is headquartered in EmeryVille, US.